• news.cision.com/
  • Panion/
  • Board and management members of Panion Animal Health AB (publ), subscribes for shares in the current emission
English

Board and management members of Panion Animal Health AB (publ), subscribes for shares in the current emission

Report this content

Panion Animal Health AB (“Panion”) is currently offering existing shareholders and others the rights to subscribe for shares in the emission running from 16 – 30 May 2018. The Board of Panion has decided the issue with preference for existing shareholders of a total of approximately SEK 9.2 million.

http://panion-animalhealth.com/emisson/

Earlier this week, the CEO of Panion, Anja Holm, announced that she will subscribe for 100.000 SEK in the emission. Now the board members in Panion, Lars Friis Mikkelsen and Dede Willis, the Chief Financial Officer Sofia Josephson, and the Business Development Director Carlos Velez announce that they will also subscribe for shares in the current emission.

Anja Holm says: “I am very pleased with that, because it reflects the dedication and confidence that the members of the management and board have in our progress and prospect, which is very reassuring. We all work hard to move the project forward and we invest competence, qualifications, time, and money, because we want to succeed. With the recent good news from CombiGene on EU-funding, we believe in a fast development that will also benefit Panion’s work.”

Subscription period 16 May - 30 May 2018
Subscription price 1,14 SEK per share

This press release contains information which Panion Animal Health AB is obliged to publish according to the EU market abuse regulation (MAR). This information was submitted by Panion’s CEO, Anja E. H. Holm, for publication on May 28 2018.

Anja E. H. Holm, CEO
+ 45-22 94 66 00
anja.holm@panion-animalhealth.com

Bolaget ska utveckla och kommersialisera genterapi för behandling av epilepsiliknande tillstånd hos hundar och andra djur, samt utveckla och kommersialisera andra veterinärmedicinska produkter och nya behandlingsformer som kan ge sjuka djur bättre livskvalitet.
Panion will develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, and other new animal health products and treatments that improve the quality of life for animals suffering from chronic diseases.

Documents & Links